Hospital
Sullivan County Community Hospital
Sullivan County Community Hospital was paid $10.25M by Medicaid between Jan 2018 and Nov 2024, across 174 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 14% of everything it billed.
33Billing provider infoSULLIVAN COUNTY COMMUNITY HOSPITAL
SULLIVAN, IN 47882
SULLIVAN, IN 47882
33aNPI1497759260assigned 06/09/2005
33bProvider typeCritical Access Hospital
28Total paid$10.25M
24GClaims293,942
24DCodes billed174
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in Indiana
Rank by total paid#1 of 26
Median peer was paid$4.16M
This provider vs. median2.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 29,535 | $311K | |
| 2019 | 28,819 | $804K | |
| 2020 | 28,304 | $738K | |
| 2021 | 51,403 | $1.68M | |
| 2022 | 72,062 | $2.55M | |
| 2023 | 48,380 | $2.43M | |
| 2024incomplete | 35,439 | $1.74M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 14% | 22,780 | 14,121 | $1.42M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 13% | 32,329 | 18,184 | $1.36M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 9,465 | 7,816 | $1.31M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.9% | 11,928 | 8,756 | $907K |
| 64493 | 5.5% | 1,055 | 439 | $559K | |
| 64635 | 5.0% | 524 | 153 | $511K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.2% | 591 | 128 | $226K |
| 71045 | Radiologic examination, chest; single view | 2.0% | 1,682 | 1,247 | $209K |
| 20610 | 2.0% | 2,238 | 800 | $205K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.8% | 1,931 | 1,528 | $186K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.8% | 5,901 | 4,694 | $184K |
| 64494 | 1.7% | 625 | 290 | $173K |
162 more codes
| 64483 | 1.5% | 400 | $157K | |
| 90837 | Psychotherapy session, about an hour | 1.5% | 1,697 | $157K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 3,041 | $156K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 2,095 | $139K |
| 36000 | 1.3% | 2,474 | $136K | |
| 20553 | 1.3% | 1,687 | $135K | |
| 80053 | Comprehensive metabolic panel | 1.3% | 22,891 | $129K |
| 64636 | 1.3% | 261 | $128K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 629 | $128K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 1,950 | $117K |
| 36415 | Collection of venous blood by venipuncture | <1% | 48,381 | $101K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,827 | $101K |
| 11721 | <1% | 2,469 | $91K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 21,308 | $91K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 538 | $88K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,059 | $87K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,076 | $72K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,664 | $72K |
| 94760 | <1% | 953 | $63K | |
| G0378 | Hospital observation service, per hour | <1% | 312 | $63K |
| Q3014 | Telehealth originating site facility fee | <1% | 1,047 | $60K |
| 64484 | <1% | 145 | $57K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,007 | $46K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 367 | $38K |
| 64490 | <1% | 75 | $37K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 429 | $36K |
| 87631 | <1% | 386 | $24K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 526 | $23K |
| 73630 | <1% | 990 | $22K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 272 | $22K |
| 59426 | <1% | 296 | $21K | |
| 59425 | <1% | 278 | $20K | |
| 84484 | <1% | 2,765 | $20K | |
| 64491 | <1% | 36 | $17K | |
| 29580 | <1% | 434 | $17K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 235 | $15K |
| 81001 | <1% | 7,632 | $14K | |
| 27096 | <1% | 249 | $14K | |
| 62323 | <1% | 28 | $13K | |
| 80061 | Lipid panel | <1% | 1,542 | $13K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,293 | $12K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 417 | $12K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,021 | $12K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 417 | $12K |
| 83605 | <1% | 1,622 | $9K | |
| 93041 | <1% | 741 | $9K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 140 | $9K |
| 99285 | Emergency room visit (most serious) | <1% | 221 | $9K |
| 81002 | <1% | 5,462 | $8K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 85 | $8K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 324 | $8K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 709 | $8K |
| 76942 | <1% | 522 | $8K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,721 | $7K |
| 85027 | <1% | 2,148 | $7K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 50 | $7K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 30 | $6K |
| 82570 | <1% | 3,321 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 414 | $6K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 79 | $6K |
| 83721 | <1% | 1,522 | $5K | |
| 81003 | <1% | 2,635 | $5K | |
| 83690 | <1% | 1,667 | $5K | |
| 81015 | <1% | 1,719 | $4K | |
| 82150 | <1% | 1,215 | $4K | |
| 83986 | <1% | 3,244 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 918 | $4K |
| 87430 | <1% | 336 | $4K | |
| 73610 | <1% | 126 | $3K | |
| 72100 | <1% | 1,590 | $3K | |
| 87428 | <1% | 85 | $3K | |
| 87400 | <1% | 393 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 14 | $2K |
| 81025 | <1% | 945 | $2K | |
| 84439 | <1% | 309 | $2K | |
| 72020 | <1% | 1,033 | $2K | |
| 87040 | <1% | 362 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 13 | $2K |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 790 | $2K |
| 83880 | <1% | 61 | $2K | |
| 99205 | Prolong outpt/office vis | <1% | 18 | $2K |
| 85379 | <1% | 246 | $2K | |
| 72202 | <1% | 58 | $1K | |
| 84702 | <1% | 155 | $1K | |
| 87625 | <1% | 86 | $1K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 41 | $1K |
| 82947 | <1% | 1,837 | $1K | |
| 84703 | <1% | 558 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 15 | $1K |
| 83735 | <1% | 276 | $663.37 | |
| 87070 | <1% | 110 | $612.13 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 15 | $611.60 |
| 86592 | <1% | 170 | $529.09 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 5,075 | $500.84 |
| 72040 | <1% | 179 | $448.18 | |
| 82607 | <1% | 39 | $422.24 | |
| 81000 | <1% | 535 | $401.78 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 15 | $374.44 |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 19 | $362.88 |
| 96127 | <1% | 240 | $342.29 | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 302 | $341.60 |
| 87280 | <1% | 25 | $301.56 | |
| 84144 | <1% | 16 | $256.58 | |
| 85610 | <1% | 100 | $255.11 | |
| 87660 | <1% | 15 | $234.60 | |
| 87480 | <1% | 15 | $234.60 | |
| 87510 | <1% | 15 | $234.60 | |
| 83970 | <1% | 14 | $222.40 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 268 | $215.47 |
| 83540 | <1% | 47 | $213.51 | |
| 87420 | <1% | 16 | $206.55 | |
| 99000 | <1% | 24 | $155.60 | |
| 83550 | <1% | 28 | $148.58 | |
| 83655 | <1% | 12 | $145.32 | |
| 86308 | <1% | 34 | $138.54 | |
| 86160 | <1% | 15 | $123.56 | |
| 76000 | <1% | 18 | $108.84 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 170 | $98.00 |
| 85730 | <1% | 21 | $96.15 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 38 | $74.81 |
| 82043 | <1% | 56 | $69.36 | |
| 82950 | <1% | 15 | $52.25 | |
| 86901 | <1% | 46 | $50.54 | |
| 96160 | <1% | 105 | $45.36 | |
| 86850 | <1% | 28 | $41.68 | |
| 82962 | <1% | 102 | $37.31 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 931 | $35.62 |
| 86900 | <1% | 28 | $23.92 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,138 | $13.45 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 17 | $9.77 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,635 | $9.61 |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | 0% | 216 | $0.00 |
| G8482 | Influenza immunization administered or previously received | 0% | 71 | $0.00 |
| 99310 | Prolong nursin fac eval 15m | 0% | 33 | $0.00 |
| 1090F | 0% | 172 | $0.00 | |
| 3078F | 0% | 180 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 219 | $0.00 |
| 0518F | 0% | 191 | $0.00 | |
| G8598 | Aspirin or another antiplatelet therapy used | 0% | 15 | $0.00 |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | 0% | 152 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 88 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 107 | $0.00 |
| 4040F | 0% | 66 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 48 | $0.00 |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 25 | $0.00 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 127 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 53 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 380 | $0.00 |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 0% | 449 | $0.00 |
| 1101F | 0% | 225 | $0.00 | |
| 3074F | 0% | 246 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 267 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 324 | $0.00 |
| 1036F | 0% | 440 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 245 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 18 | $0.00 |
| 3008F | 0% | 259 | $0.00 | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | 0% | 32 | $0.00 |
| A9270 | Non-covered item or service | 0% | 27 | $0.00 |
| 1125F | 0% | 31 | $0.00 | |
| G9664 | Patients who are currently statin therapy users or received an order (prescription) for statin therapy | 0% | 15 | $0.00 |
| 0509F | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFRANKLIN, MICHELLE (CEO)
| Provider | Location | Paid |
|---|---|---|
| Mso Clinics, INC. | Sullivan, IN | $542K |
| Mso Clinics, INC. | Sullivan, IN | $512K |
| Mso Clinics, INC. | Sullivan, IN | $288K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.